Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Global Blood Therapeutics
Biotech
Pfizer's SCD drug fails ph. 3 study in latest blow to GBT legacy
Pfizer’s sickle cell disease drug flunked a key phase 3 test, the latest blow to the pharma’s $5.4 billion acquisition of Global Blood Therapeutics.
James Waldron
Aug 18, 2025 7:31am
Fierce Biotech's Rotten Tomatoes of 2024
Dec 16, 2024 3:00am
ASH: Pfizer swims in crowded sickle cell, hemophilia waters
Dec 9, 2023 7:00pm
Pfizer's $5.4B GBT buy adds potential sickle cell disease 'cure'
Aug 8, 2022 10:19am
Forma builds case for FT-4202 in competitive sickle cell space
Mar 30, 2021 8:40am
GBT adds 2 Sanofi sickle cell meds in deal worth up to $353M
Mar 16, 2021 9:55am
